Continuous Revlimid May Improve Outcomes in Newly Diagnosed Multiple Myeloma
Among older patients with newly diagnosed multiple myeloma, treatment with Revlimid® (lenalidomide) in combination with melphalan and prednisone, followed by Revlimid maintenance therapy (MPR-R) may...
View ArticleRelatively Low Incidence of Secondary Cancers After Use of Revlimid for...
Three separate studies have suggested that the benefit of Revlimid® (lenalidomide) for the initial treatment of patients with multiple myeloma outweighs the possible increased risk of developing...
View ArticleMini-Transplants Continue to Show Promise for Older Patients with Multiple...
Less toxic cancer treatment followed by an allogeneic stem cell transplant is showing promise for older patients with advanced blood and bone marrow cancers such as multiple myeloma. These results were...
View ArticleVelcade Improves Survival with Multiple Myeloma
Final results from the VISTA trial demonstrate that the addition of Velcade® (bortezomib) to melphalan and prednisone substantially improves overall survival among patients with previously untreated...
View ArticleCarfilzomib Promising in Newly Diagnosed Multiple Myeloma
The investigational drug carfilzomib, in combination with Revlimid® (lenalidomide) and low-dose dexamethasone, produced high response rates in patients with newly diagnosed myeloma. The results of this...
View ArticleRevlimid Increases Risk of Some New Cancers
Patients with newly diagnosed multiple myeloma who receive Revlimid® (lenalidomide) may be at an increased risk of developing new cancers, according to a safety announcement released by the U.S. Food...
View ArticleThree Studies Show Revlimid Provides Benefits—and Risks—in Multiple Myeloma
Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three...
View ArticleVelcade Effective for Induction and Maintenance Treatment of Multiple Myeloma
Velcade® (bortezomib) during induction and maintenance treatment improves survival in newly diagnosed stage II or III multiple myeloma, according to the results of a study published in the Journal of...
View ArticleMLN9708 “Oral Velcade” Shows Promise in Multiple Myeloma
The investigational, oral proteasome inhibitor MLN9708, which is a new version of Velcade® (bortezomib)—may be more effective and better tolerated than the Velcade injections, according to data from a...
View ArticlePomalidomide Improves Survival in Refractory Multiple Myeloma
Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory...
View ArticleCancerConnect Marks Milestone in Multiple Myeloma Community
Fort Worth TX/Sun Valley ID - CancerConnect is the leading Social Media Application for Cancer patients and caregivers seeking information and support in the wake of a cancer diagnosis. With over...
View ArticleKyprolis/Revlimid/Dexamethasone Produces Durable Responses in Relapsed...
The combination of Kyprolis® (carfilzomib), Revlimid® (lenalidomide), and low-dose dexamethasone was well tolerated and produced durable responses in patients with relapsed progressive multiple...
View ArticlePanobinostat Plus Velcade and Dexamethasone Shows Promise in Heavily...
The experimental drug panobinostat (LBH-589) in combination with Velcade® (bortezomib) and dexamethasone is effective for heavily pretreated multiple myeloma, according to the final results from a...
View ArticleRevlimid After Stem Cell Transplantation Delays Progression of Myeloma, but...
In a Phase III clinical trial among patients who had undergone stem cell transplantation for multiple myeloma, post-transplant maintenance therapy with Revlimid® (lenalidomide) significantly delayed...
View ArticleClik here to view.
Have a Question about Multiple Myeloma? Join us on March 26th and 27th
CancerConnect and Roswell Park Cancer Institute Will Present: Ask the Expert with Dr. Holstein CancerConnect has partnered with Roswell Park Cancer Institute to provide you with the opportunity to...
View ArticleContinuous Revlimid/Lose-Dose Dexamethasone Improves Outcomes in Newly...
Among people with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation, continuous treatment with Revlimid® (lenalidomide) and low-dose dexamethasone results in better...
View ArticleRevlimid Linked with Second Primary Malignancies in Patients with Myeloma
Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results...
View ArticleTreanda/Velcade/Dexamethasone Produces High Response Rate in...
The combination of Treanda® (bendamustine), Velcade® (bortezomib) and dexamethasone produced a high response rate in patients with relapsed/refractory multiple myeloma, according to the results of a...
View ArticleMultiple Myeloma Q&A with Roswell Park Cancer Institute Expert
CancerConnect recently partnered with Roswell Park Cancer Institute to provide you with the opportunity to engage with a multiple myeloma expert, Sarah Holstein, MD, PhD. Dr. Holstein was a guest...
View ArticleClik here to view.
Ask the Expert Tips: Multiple Myeloma
Sarah Holstein, MD, PhD from Roswell Park Cancer Institute recently answered your questions on multiple myeloma as part of CancerConnect’s Guest Moderator Ask the Expert series. Dr. Holstein is an...
View Article
